Copenhagen-based biotech company Biograil has raised €20 million in a financing round backed by Verve Ventures, Megatrend Invest and existing investor High-Tech Gründerfonds (HTGF), which participated through its HTGF Opportunity growth fund. The company is developing BIONDD®, an oral drug delivery device designed to enable the administration of therapeutics, including biologic drugs and medicines currently delivered by injection, through a standard-sized capsule. The new funding will support preparations for Phase 1 clinical trials, including non-clinical Good Laboratory Practice (GLP) studies and the establishment of a Good Manufacturing Practice (GMP) production process, ahead of a planned larger financing round in 2027. Biograil...
Læs hele artiklen hos kilden.
Kommentarer (0)
Ingen kommentarer ennå. Bli den første til å kommentere!